Axsome Therapeutics (AXSM) Inventory (2022 - 2026)

Axsome Therapeutics has reported Inventory for 5 years, with the latest figure at $31.5 million in Q1 2026.

• Quarterly Inventory rose 93.12% year-over-year to $31.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $31.5 million (up 93.12% YoY) and the FY2025 annual result came in at $27.9 million, up 77.59% from the prior year.
• Inventory climbed to $31.5 million in Q1 2026 per AXSM's latest filing, from $27.9 million in the prior quarter.
• Over five years, Inventory peaked at $31.5 million in Q1 2026 and troughed at $4.3 million in Q4 2022.
• A 5-year average of $16.3 million and a median of $15.2 million in 2023 frame the typical range for Inventory.
• The sharpest annual moves came in 2023 and 2025: Inventory surged 250.35% in 2023, then tumbled 38.6% in 2025.
• Over 5 years, Inventory stood at $4.3 million in 2022, then soared by 250.35% to $15.1 million in 2023, then rose by 3.94% to $15.7 million in 2024, then surged by 77.59% to $27.9 million in 2025, then grew by 12.8% to $31.5 million in 2026.
• According to Business Quant data, Inventory over the past three periods registered $31.5 million, $27.9 million, and $23.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.